{"id":134565,"date":"2023-08-29T13:29:00","date_gmt":"2023-08-29T13:29:00","guid":{"rendered":"https:\/\/allmybiznews.com\/?p=134565"},"modified":"2023-08-29T13:29:00","modified_gmt":"2023-08-29T13:29:00","slug":"factbox-court-challenges-to-medicare-drug-price-negotiation-plan","status":"publish","type":"post","link":"https:\/\/allmybiznews.com\/markets\/factbox-court-challenges-to-medicare-drug-price-negotiation-plan\/","title":{"rendered":"Factbox-Court challenges to Medicare drug price negotiation plan"},"content":{"rendered":"
(Reuters) – The U.S. government on Tuesday selected the first 10 drugs, including the big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer, that will be subject to the first-ever Medicare price negotiations, part of President Joe Biden\u2019s Inflation Reduction Act (IRA) that drugmakers and industry groups have challenged in court.<\/p> At least eight lawsuits were filed between June and late August seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution. The following are key details of the lawsuits:<\/p>\n Company Date Location Drugs named<\/p>\n filed in lawsuit<\/p>\n as likely to<\/p>\n be affected<\/p>\n by IRA<\/p>\n Merck & Co June 6 U.S. District Court Diabetes<\/p>\n for the District of drugs<\/p>\n Columbia Januvia and<\/p>\n Janumet,<\/p>\n cancer<\/p>\n treatment<\/p>\n Keytruda<\/p>\n The U.S. June 9 U.S. District Court NA<\/p>\n Chamber of for the Southern<\/p>\n Commerce District Of Ohio<\/p>\n Western Division<\/p>\n Bristol Myers June 16 U.S. District Court Blood<\/p>\n Squibb for the District of thinner<\/p>\n New Jersey Eliquis,<\/p>\n cancer<\/p>\n therapy<\/p>\n Opdivo<\/p>\n Astellas July 14 U.S. District Court Prostate<\/p>\n Pharma For The Northern cancer drug<\/p>\n District of Illinois, Xtandi,<\/p>\n Eastern Division Myrbetriq<\/p>\n for treating<\/p>\n overactive<\/p>\n bladder<\/p>\n Johnson & July 18 U.S. District Court Blood<\/p>\n Johnson for the District of thinner<\/p>\n New Jersey Xarelto<\/p>\n Pharmaceutica June 21 U.S. District Court NA<\/p>\n l Research For the Western<\/p>\n and District Of Texas<\/p>\n Manufacturers Austin Division<\/p>\n of America<\/p>\n Boehringer Aug 18 U.S. District Court Diabetes<\/p>\n Ingelheim for the District Of drug<\/p>\n Connecticut Jardiance<\/p>\n AstraZeneca Aug 25 U.S. District Court Cancer drug<\/p>\n For the District Of Lynparza,<\/p>\n Delaware blood<\/p>\n disorder<\/p>\n treatment<\/p>\n Soliris<\/p>\n